Оценка влияния комбинированной терапии милдронатом на липидный спектр, факторы воспаления и функцию эндотелия у больных ишемической болезнью сердца

И. В. Сергиенко, Valery V. Kukharchuk, С. А. Габрусенко et al. · Рациональная фармакотерапия в кардиологии · 2007

Aim. To study the effect of treatment with metabolic corrector mildronate on lipid profile, inflammatory factors and endothelium function in patients with ischemic heart disease (IHD) Material and methods. 60 patients with IHD (stable exertional angina, II-IV functional class) were included in to the study. They were split in two groups. Patients of the main group (n = 30) were treated with mildronate (1 000 mg per day during 3 months) combined with standard therapy. Patients of the second group (n = 30) received the standard therapy only. Total cholesterol (TC), triglycerides (TG), cholesterol of low density lipoproteid (LDL-C), cholesterol of high density lipoproteid (HDL-C), aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), creatine kinase (CK), C-reactive protein (CRP), interleukin-б (IL-6), lipoprotein (α) (Lp(α)), NО3 were determined. Besides endothelium dependent vasodilatation of brachial artery was studied Results. TC, HDL-C and TG levels did not differ before and after treatment with mildronate, but LDL-C level significantly reduced (from 3.06 ± 1.32 to 2.7 ± 1.0 mmol / l, p 0.05). The significant change of Lp(α) was not found in both groups. Increase in endothelium dependent vasodilatation was noted after mildronate treatment. Besides increase in NО3 level in blood was detected (from 33.5 ± 1 0.0 to 44.1 ± 32.3 µmоI / I, р

Cited by 0 works.

Authors